Tell us about your renal conferences
Presented at 3 international renal conferences, twice at ERA and once at ASN
2 weeks ago I went to UKKW for the first time
Just submitted abstract for ERA’26
Tell us about your COVID-19 antibody work
A cohort study of 63 renal transplant patients
We looked at the anti-spike antibodies titres following their 3rd ‘booster’ dose
Despite three doses of the vaccine, some high-risk renal transplant patients remain vulnerable to COVID-19 and fail to develop an adequate humoral response to the vaccine
Tell us about your IgAN case report
IgAN associated with anti-synthetase syndrome (ILD, arthritis and myositis) and chronic granulomatous disease (primary immunodeficiency where patients have recurrent infections and abnormal inflammatory responses result in granuloma formation)
Tell us about your ANCA vasculitis work
Incidence of newly diagnosed AAV was observed from 1st January to 30th April 2023
Suggested a four-fold increase in the incidence of AAV, as compared to data averages from the same centre for the previous decade
More diagnoses were of the MPA phenotype, contradicting previous studies suggesting a higher prevalence of GPA in northern Europe
Tell us about your paper on ANCA negative vasculitis
A retrospective, multicenter cohort study was conducted from 2002 to 2022 and included those with biopsy-proven PIGN
ANCA-negative patients were younger, more commonly presented with renal-limited disease, had worse estimated glomerular filtration rate at diagnosis and higher rates of proteinuria
They had higher rates of end-stage kidney disease
Adverse outcomes may result from delays in diagnosis, advanced disease at presentation, and less intense immunosuppressive treatment
Tell us about the work you’re doing on MACE in nephrotic syndrome
Just submitted abstract for ERA’26
NS is associated with increased cardiovascular morbidity and mortality (1) though contemporary UK-based estimates of major adverse cardiovascular events (MACE) in these conditions are lacking
Evidence for renal predictors of cardiovascular risk in this population is also limited
There were 149 consecutive patients included in our cohort and over the 10-year follow-up, a MACE occurred in 19 patients,
corresponding to a cumulative incidence of 21%
Patients who failed to achieve complete or partial remission were at significantly
higher risk of MACE compared with those achieving remission
Tell us about your audit on SGLT-2i in primary care
Poor compliance
Indications have changed and broadened since then so I suspect compliance to guidelines will be ever poorer
Seemed main barriers were incorrect coding on EMIS and poor knowledge of indications
Tell us about your hyperkalaemia audit
This quality improvement project demonstrated that simple, low-cost interventions can improve adherence to local hyperkalaemia management guidelines in an acute hospital setting
The use of visual cognitive aids was associated with improved compliance with key elements of care, including ECG monitoring and appropriate pharmacological management
However, improvements in guideline adherence were not accompanied by improvements in the timeliness of time-critical interventions
Future improvement efforts should therefore focus on system-level solutions, including embedded electronic alerts, structured escalation pathways, and clearer allocation of responsibility within acute workflows
Tell us about the ESENeph revision day
Prof Bhandari and Prof Salama
Tell us about the IKNET meeting
Lupus nephritis Dr Brix
Biomarkers in nephrotic syndromes Prof in Bristol
Tell us about the EMU for renal medicine
Approach to oedematous patient
PCKD
Reduced eGFR who should see a nephrologist
Tell us about the RSM Round Up
International speakers
Jonathan Barratt discussing IgA nephropathy
Novel treatments
Addressing CV complication in CKD patients
Antibody-mediated rejection
Personalised HD
Tell us about the UKKA Advanced Nephrology Course
The course focuses on key areas of renal medicine including glomerular disease, dialysis modalities, transplantation, electrolyte disorders and renal pathology
It combines lectures from experienced nephrologists with case-based discussions, which I found particularly helpful for linking physiology to clinical practice
Are you planning on going to any other conferences this year?
ERA if work gets accepted
What makes you suitable for renal?
I think several factors make renal a particularly good fit for me
Firstly, I enjoy the intellectual challenge of nephrology
Workload demanding- organised as evidenced by my ability to balance clinical work with academic work and roles such as IMT rep for RDC and co-ordinating regional IMT teaching
Keen eye for research- having done multiple projects over the last few years- makes a specialty that is rapidly evolving a good fit for me
I think my communication skills lend themselves to renal medicine involves managing patients longitudinally and building strong relationships and managing patients holistically
How can you evidence your commitment to specialty?
Clinically- I’ve sought exposure to renal patients- using all of my allocated SDT/CPD time- during training and have developed experience managing renal patients on the take
Academically, I have presented research at three international conferences (twice at ERA and once at ASN), and attended UKKW 2 weeks ago
Which allowed me to engage with the wider nephrology community and stay updated with current developments in the field
And had work I co-authored published in Kidney International reports last year
I have also attended nephrology-focused educational events such as the UKKA Advanced Nephrology Course on Oxford and a revision day for the SCE in Birmingham- which I’m hoping to sit in October- which helped strengthen my core knowledge and confirm my interest in pursuing nephrology as a career
I’m a member of the UKKA and also subscribed to NephJC to stay up to date with recent developments
Tell us about your strengths and weaknesses
One of my key strengths is organisation and situational awareness, particularly when managing the acute medical take
Voted in as IMT rep for Resident Doctor’s committee at my trust this year and last year was voted to coordinate the regional IMT teaching
Communication- CS received an email from clinical director at The Christie after seeing my patient interactions there complimenting my communication skills
And was awarded ‘Kindest Colleague’ award following an oncology rotation
I’m also proactive in my learning and professional development
For example, I have sought opportunities to deepen my nephrology knowledge through courses and conferences, and have presented work at several international meetings
One area I’m currently working on is ensuring I maintain a balance between clinical commitments and academic interests
I tend to take on multiple projects and teaching opportunities, which can stretch my time
To address this, I’ve been prioritising more carefully and focusing on completing key projects efficiently before taking on additional work
Where do you see yourself in 5-10 years
In five years I hope to be an established renal registrar progressing towards consultancy with a strong academic component to my career. I am particularly interested in pursuing a PhD during training meanwhile contributing to teaching in department
How do you think the specialty will evolve
Chronic kidney disease (CKD) will become the fifth global case of death by 2040
Medications in last decade: GLP-1, finerenone, ASIs, HIF stabilisers, fish oil (!) PISCEs trial, avacopan, IgA drugs like sparsentan and Kinpeygo, obinutuzumab
Therapeutics: xenotransplantation, stem-cell therapies
Diagnostics: biomarkers, proteomics, imaging
